02050nam a2200469 i 4500001001300000003000600013005001700019007001400036008004100050040002300091042000800114043001200122050001900134074001600153086002700169099002700196245021100223264006000434264010100494300006000595336000800655337001600663338001900679490002200698500006800720500003600788500002100824500002500845504004100870533010800911650003901019650005301058650004101111650004501152610002701197655003401224710007701258776010101335776010201436830002301538999001901561ocn946944315OCoLC20160809093803.0he bmb024bbca160419s2015    dcua    bb   f000 0 eng c  aGPObengerdacGPO  apcc  an-us---14aKF31b.F5 2015  a1038-B (MF)0 aY 4.F 49:S.PRT.114-20/  aY 4.F 49:S.PRT.114-20/04aThe price of Sovaldi and its impact on the U.S. health care system /cprepared by the staffs of ranking member Ron Wyden and committee member Charles E. Grassley, Committee on Finance, United States Senate. 1aWashington :bU.S. Government Publishing Office,c2015. 2aWashington, DC :bFor sale by the Superintendent of Documents, U.S. Government Publishing Office  a2 volumes (viii, 1980 pages) :billustrations ;c24 cm.  btxt  bh2rdamedia  bhe2rdacarrier1 aS. prt. ;v114-20  aAt head of title: 114th Congress, 1st session. Committee print.  aShipping list no.: 2016-0082-M.  a"December 2015."  aCRDP Project record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2016]e34 microfiches : negative. 0aSofosbuvirxPriceszUnited States. 0aHepatitis CxChemotherapyzUnited StatesxCosts. 0aSulfonamidesxPriceszUnited States. 0aAntiviral agentsxPriceszUnited States.20aGilead Sciences (Firm) 7aLegislative materials.2lcgft1 aUnited States.bCongress.bSenate.bCommittee on Finance,eissuing body.08iPrint version:tPrice of Sovaldi and its impact on the U.S. health care systemw(OCoLC)93201902808iOnline version:tPrice of Sovaldi and its impact on the U.S. health care systemw(OCoLC)932136752 0aS. prt. ;v114-20.  c253290d253290